In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: - Which patients should have pharmacokinetic-guided therapy?
- Toxicities with PEGylated extended half-life products
- Factor VIII and bone health
- Factor VIII peaks, thrombotic risk, and cardiovascular disease
- Choosing between extended half-life products and emicizumab for active patients
- Role of fitusiran in the treatment paradigm if approved
Presenters:
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas Mark Reding, MD
Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director
Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and
Thrombosis Center
Children’s Hospital Los Angeles
University of Southern California
Keck School of Medicine
Los Angeles, California |
Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
